De-risked product
Manufacturing readiness
Complete final laboratoryreporting, statistics andpublication and IP work.
Investors & partnerships
Clinical evidence platformready for market entry
T-Booster combines completed participant involvement, UK GMP manufacturing readiness, preliminary biological signals, experienced leadership and differentiated thymus-focused positioning.
£700K+Founder-funded developmentcommitment to date.
66,000 capsulesManufactured for theclinical programme.
260 volunteersParticipant involvementhas been completed.
2026 targetCommercial-launch workis now underway.
Why T-Booster, why now
A differentiatedscience-led opportunity
The company is between completed clinical execution and commercial entry. Capital is intended to unlock final evidence, IP, production, distribution and disciplined launch.
De-risked execution
Clinical execution
Scale manufacturing,packaging, inventory andquality and logistics.
Differentiated positioning
Thymus-focused platform
Build market-entry campaigns,partner and retail readinessand consumer education.
Market context
A large and growingimmune-health category
Current investor materials cite a global immune-health supplement market of $86 billion in 2024, projected to reach $132 billion in 2028.
Swipe horizontally to view the complete graphic.
Market estimates should be refreshed and source-checked before investor circulation. Projections are assumptions, not guarantees.
Commercial model
Recurring revenuewith partnership options
The current model assumes a £19.99 monthly consumer price and a multi-market pathway. Structures may include licensing, distribution, strategic investment or asset-level collaboration.
D2C
Direct consumer launch
Digital customer acquisition,education-led content andsubscription retention.
Retail
Retail and specialist
Pharmacy, health retail andselected e-commerce routesas evidence and claims mature.
Distribution
Territory partners
Regional distributors canaccelerate compliance,logistics and market access.
Strategic
Licensing or acquisition
Global or territory licences,co-development options andstrategic acquisition routes.
Illustrative business outlook
Small market sharemeaningful business
The current seven-year model starts at £2.56 million gross revenue in 2027–28 and reaches £145.75 million in 2033–34, with £29.15 million net profit in the final year.
Swipe horizontally to view the complete graphic.
Forecast only. Outcomes depend on evidence, compliance, launch timing, pricing, distribution, acquisition, retention, manufacturing and working capital.
Use of funds
Capital for the transitionfrom evidence to market
The raise is designed to reduce scientific, regulatory, production and commercial risk.
Evidence & IP
Final evidence and IP
Complete final laboratoryreporting, statistics andpublication and IP work.
Supply & launch
Production capital
Scale manufacturing,packaging, inventory andquality and logistics.
Commercial growth
Marketing and distribution
Build market-entry campaigns,partner and retail readinessand consumer education.
Risk and mitigation
An investor-ready view ofwhat remains to be proven
The website avoids guaranteed approval, launch, returns, licensing or acquisition.
Final clinical interpretation
Complete blinded group analysis, statistical review, scientific writing and peer review.
Claims and regulatory compliance
Develop market-specific claims matrices and obtain specialist review before promotion.
Consumer adoption
Use staged launch tests, retention tracking and channel diversification.
Manufacturing and working capital
Stage production, validate suppliers and protect cash conversion.
IP defensibility
Coordinate patents, confidentiality, trademarks and freedom-to-operate review.
Platform potential
More than oneproduct concept
The programme can support future immune-ageing, skin, men’s and women’s health extensions, subject to separate formulation, testing and compliant positioning.
Core
T-Booster platform
Lead product centred on thymus function and healthy immune ageing.
Extension 01
Skin and healthy ageing
Future concept requiring separate formulation and substantiation.
Extension 02
Men’s health
Future sub-product with its own evidence and claims pathway.
Extension 03
Women’s health
Future sub-product with its own evidence and claims pathway.